Mohammad AskarPublic working copy · medical review pending

Glaucoma · 012

Pigmentary glaucoma: recognise damage and assess secondary mechanisms

Distinguish pigment dispersion from glaucoma. Keep the broader original secondary-glaucoma examples in context and plan pressure control,causal treatment and monitoring together.

Working copy published: 2026-11-06T03:47:16+01:00. Source, translation and medical checks remain open. Limitations are stated in the text and references. Editorial text version: 2026-11-04 07:48 CET.

Pigment alone is not glaucoma. Document pressure,nerve,field and angle; treat the actual risk or damage. In secondary disease,identify the cause and any evolving angle closure rather than applying one laser or drug recipe to every eye.

Terminology and draft status

Selected Arabic terms were directly checked in WHO UMD; exact matches and missing compounds are recorded in the terminology ledger. Remaining compounds and full clinical translations remain working copies for further review. Source and medical checks remain pending.

01Recognise pigment dispersion and document damage

Pigment dispersion syndrome (PDS) releases iris pigment that can obstruct trabecular outflow and raise intraocular pressure (IOP). Pigmentary glaucoma (PG) requires glaucomatous optic neuropathy; pigment or a pressure rise alone does not establish it. Young or middle-aged myopic men are a familiar presentation, but other patients can be affected. 1

Posterior iris concavity and reverse pupillary block can bring the posterior pigment epithelium into contact with the zonules. Look for a Krukenberg spindle, midperipheral radial iris transillumination and dense trabecular pigment. The signs vary; a Krukenberg spindle is not pathognomonic. 1

Gonioscopy assesses angle width, pigment distribution and secondary mechanisms. A Sampaolesi line is pigment anterior to Schwalbe’s line and also occurs in pseudoexfoliation; it is not a PG-specific diagnostic sign. Document the disc/RNFL, OCT and reliable visual fields to distinguish risk from damage and later progression. 1

An older community cohort estimated conversion at 10% after 5 years and 15% after 15 years. Its retrospective ascertainment, few events and historical endpoint, which included pressure-related treatment, limit transfer to a modern individual diagnosis. These figures are not a universal forecast or a treatment indication. 2

02Choose pressure treatment and assess laser risk

For PG, pressure lowering follows the principles used for other open-angle glaucomas. Set the target from damage, progression and lifetime visual risk; consider medication, suitable laser or surgery. A heavily pigmented angle without relevant pressure risk or damage is not itself an indication for treatment. 1

Selective laser trabeculoplasty (SLT) can cause marked pressure spikes in densely pigmented angles. Use cautious energy selection, appropriate prophylaxis and pressure review for the eye and device. Low power is a principle, not proof that one fixed energy or an inferior-only treatment extent is correct for every PG eye. 1 3

A retrospective matched comparison of 65 PG and 65 POAG eyes recorded early spikes in 5/65 versus 0/65 eyes (p=0.058), despite lower total energy in PG. Few events, different medication patterns and non-random treatment limit precision and causal inference; a non-significant comparison does not establish equal safety. 3

YAG peripheral iridotomy may flatten a concave iris by changing the pressure relationship. Anatomical improvement is not proof that glaucoma or visual-field loss is prevented. Evidence for routine prophylactic iridotomy in PDS/PG is uncertain; selected clinical indications require a separate risk–benefit decision. 1 4

Choose pressure treatment and assess laser risk
TreatmentDecision and safety
SLT in dense pigmentCautious individual energy/extent,prophylaxis and pressure review; no universal inferior-only recipe
YAG peripheral iridotomyMay alter iris configuration; prevention of glaucoma/field loss not established for routine prophylaxis

03Recognise pseudoexfoliation and plan for zonular weakness

Pseudoexfoliative glaucoma (PEXG, also PXFG) is an important secondary open-angle form with substantial geographical variation. Fibrillar material affects trabecular outflow and the zonules; associated systemic findings do not prove one systemic treatment for the ocular disease. Look for a central lens-capsule disc, a clear intermediate zone and a peripheral material ring. 1

Phacodonesis, poor dilation and zonular weakness change the cataract plan. Prepare suitable pupil-expansion tools and capsule/zonular support, such as selected hooks or a tension ring, according to the defect. Distinguish pupil hooks from support of the capsular bag; no single device guarantees against capsular rupture or lens loss. 1

Pressure can be high and fluctuate, and progression risk may exceed that of POAG. Reassess the target and follow-up rather than using pigment density as a guarantee of laser success. Medication and laser can help but may lose effect; cataract extraction is not automatically sufficient glaucoma treatment. 1

04Treat neovascular glaucoma and its ischaemic cause urgently

Neovascular glaucoma (NVG) can begin with an open angle covered by abnormal vessels and progress to synechial closure as a fibrovascular membrane contracts. Consider proliferative diabetic retinopathy, ischaemic central retinal vein occlusion (CRVO) and ocular ischaemic syndrome (OIS). Examine iris and angle vessels and the posterior segment; a particular pressure number is not required to recognise the threat. 1 9 13 14

Pain, corneal oedema, visual potential and angle closure determine urgency and the pressure plan. Coordinate medical pressure lowering, inflammation/pain control and appropriate glaucoma procedures with treatment of retinal ischaemia. Do not postpone dangerous-pressure management simply to follow a rigid laser-first sequence. 1 9 14

Anti-VEGF can produce rapid but temporary neovascular regression; it does not reverse established synechiae. Panretinal photocoagulation (PRP) addresses the retinal angiogenic drive when indicated and feasible. Timing and delivery depend on retinal disease, visibility and the whole eye; neither a fixed spot count nor a small central “island” is a universal treatment recipe. 1 9 14

Suspected ocular ischaemic syndrome also needs assessment of carotid and systemic vascular disease with the appropriate team. Local eye treatment alone does not address the underlying hypoperfusion. Retinal and glaucoma management should follow the cause rather than treating every NVG presentation as the same disease. 13

05Separate inflammation, viral disease and Fuchs syndrome

Inflammatory debris, trabeculitis, synechiae and steroid exposure can all raise pressure in uveitis. Determine whether the angle is open or closing and whether the inflammation is infectious. Control indicated inflammation and pressure together; reducing essential anti-inflammatory treatment without a plan can worsen the disease. 1

Fuchs uveitis syndrome may show diffuse iris atrophy, stellate keratic precipitates and mild chronic anterior inflammation with or without vitritis. The affected iris can look lighter, but heterochromia can be absent or hard to see; colour alone cannot identify the diseased eye. Typical Fuchs disease does not routinely benefit from chronic corticosteroid treatment; cataract and glaucoma need specific care. 5

Posner–Schlossman-like recurrent unilateral pressure attacks can be associated with cytomegalovirus (CMV), but prevalence varies by population and phenotype is not diagnostic. Consider selected aqueous testing when it will change management. SUN research classification relies on aqueous CMV PCR; it is not evidence that every clinical attack is CMV or that a test has perfect sensitivity. 1 6

Suspected or confirmed herpetic/CMV disease requires pathogen-appropriate antiviral planning alongside indicated inflammation and pressure treatment. Do not treat presumed viral inflammation with unprotected corticosteroid monotherapy. Corneal epithelial infection and stromal/anterior uveitic disease require different decisions; involve the relevant specialist. 1 6

06Assess steroid risk and monitor implants

Steroid pressure response depends on potency, route, dose, duration and individual susceptibility. A pressure rise and established steroid glaucoma are different outcomes; a general percentage of “high responders” cannot be transferred between topical drops, implants and diseased eyes. Review baseline nerve status, previous response and all steroid exposure. 1 7 8

SAFODEX retrospectively reviewed 421 eyes of 361 patients receiving dexamethasone implants. Ocular hypertension occurred in 28.5% of eyes over mean follow-up of 16.8 months, using a pressure or pressure-rise definition. Selected treatment, heterogeneous indications, repeated exposure and absent random controls limit causal and individual-risk interpretation. 7

Predictor findings differ across small retrospective implant cohorts, including the direction of age associations. In a 2025 series, pressure elevation followed 40/171 implants in 74 eyes; missed early visits, available-case analysis and repeated eyes/implants complicate interpretation. These data do not establish comparative long-term superiority of a particular pressure procedure. 7 10 11

The EU Ozurdex information contraindicates use in advanced glaucoma inadequately controlled by medication alone and in specified infection/capsule configurations. Check the actual label and the eye before treatment. Monitor pressure after injection and through the steroid-effect period; retinal thickness alone is not a substitute for glaucoma-risk assessment or follow-up. 8

If pressure rises, coordinate necessary inflammation control with pressure treatment. Consider a weaker steroid, steroid-sparing therapy or other changes only when suitable for the underlying disease; do not abruptly stop essential treatment without a plan. Persistent damage risk may require laser or surgery, with joint retina/uveitis/glaucoma care. 1 8

07Look for trauma, ICE and lens mechanisms

Angle recession involves injury between longitudinal and circular ciliary-body muscle fibres and may appear as a widened ciliary-body band. Compare sectors and the fellow eye. Gonioscopy is important after trauma but must not be performed on a suspected open globe; acute injury may require delayed angle examination. 1

Traumatic pressure elevation can result from blood, inflammation, lens injury or permanent outflow damage, and glaucoma can appear years later. Treat the current mechanism and arrange long-term surveillance when angle damage remains; a normal pressure today does not remove the later risk. 1

Iridocorneal endothelial (ICE) syndrome involves abnormal endothelial membrane growth onto angle/iris, producing iris distortion and peripheral anterior synechiae. It is commonly unilateral and can cause secondary angle closure. Assess cornea, pupil, iris and angle together; management depends on pressure, visual potential and the affected structures. 1

Phacolytic glaucoma results from leaked lens proteins/inflammatory material obstructing outflow around a mature cataract. Phacomorphic disease is a crowded-angle mechanism from an enlarged lens and is not simply another open-angle form. Recognise the distinction and coordinate pressure/inflammation control with definitive lens management. 1

08Plan monitoring and act on warning signs

For PDS without damage, establish baseline pressure, disc/OCT and field findings, and individualise review for pressure variability and other risk. With PG or another secondary glaucoma, reassess target, adherence and reproducible progression. New symptoms after activity or dilation, treatment changes and prior spikes can justify earlier assessment. 1

A practical plan names the mechanism, the pressure and retinal/inflammatory treatment, the next review and the emergency contact. Check new iris/angle vessels, zonular weakness and infectious clues rather than treating all secondary disease as one label. Reassess after each intervention; a quiet appearance is not proof that the cause or progression has resolved. 1 8 9 14

Sudden severe pain, blurred or reduced vision, marked redness or a painful postoperative/pressure event needs urgent assessment. Acute pressure spikes can occur despite a slowly evolving pigment syndrome. Distinguish the emergency from routine long-term surveillance and do not delay because the patient is young. 1

Plan monitoring and act on warning signs
MechanismFindingWhat to checkTreatment principle
PGMyopia/pigment and possible spikesGonioscopy plus disc/field damageIndividual pressure target; selected medication/laser/surgery with spike precautions
PEXGLens material pattern,pressure fluctuationPupil and zonules as well as glaucoma damagePressure treatment and a specific cataract/support plan when indicated
NVGNew iris/angle vessels,possible painRetinal ischaemia,angle,pressure and visual potentialTreat angiogenic drive and pressure together; temporary injection effect does not replace retinal treatment
Uveitic/Fuchs contextInflammatory signs or iris atrophyDistinguish Fuchs,viral disease and steroid responseCause-specific care plus pressure control; no blanket chronic-steroid regimen
TraumaticTrauma history,widened ciliary bandSafe-timed gonioscopy,lens/blood/inflammationTreat mechanism and pressure; long-term surveillance for permanent angle damage
Who is more often diagnosed with PDS,and what follows?

Younger to middle-aged myopic people,especially men,are a familiar group,but demographics do not establish PG or require treatment. Assess angle,pressure,nerve and function and monitor the actual risk.

What is the classic PDS clinical triad?

Krukenberg spindle,midperipheral radial iris transillumination and marked trabecular pigmentation. Expression varies; these signs are not synonymous with glaucomatous damage,and a Sampaolesi line is not PG-specific.

References and access status

  1. 1
    EGS Terminology and Guidelines for Glaucoma,6th edition (2025)

    Supplied PDF: selected angle/trauma p84,PEX/PG/lens pp129–131,uveitis/trauma/steroid pp132–135 and NVG/ICE p152 text. General target/monitoring appraisal carried from011. No complete-book or new figure inspection claimed.

  2. 2
    Siddiqui et al. PDS conversion cohort (2003),PMID12788118

    Complete indexed primary abstract read; main report unread. Historical retrospective community cohort; endpoint definitions and few events limit modern individual-risk transfer.

  3. 3
    PG/POAG matched SLT cohort (2024),PMID38470322

    Complete indexed primary abstract read; full methods/report unread. Retrospective matching,small event counts,different acetazolamide use and eye/patient structure limit safety/causal inference.

  4. 4
    Cochrane. Peripheral iridotomy for pigmentary glaucoma (2016),PMID26871761

    Indexed abstract/selected results appraisal carried from011; complete review/primary trials unread. Very-low-certainty evidence and anatomical versus functional outcomes remain distinct.

  5. 5
    SUN. Classification criteria for Fuchs uveitis syndrome (2021),PMID33845007

    Complete indexed primary abstract,selected primary introduction/discussion and extracted classification table read; full report/figure pixels unread. Consensus-selected research classification is not a universal diagnostic test.

  6. 6
    SUN. Classification criteria for CMV anterior uveitis (2021),PMID33845019

    Complete indexed primary abstract,selected methods/results/discussion and extracted tables inspected; full report/supplements/figure pixels unread. Research case selection and required PCR do not measure routine clinical test sensitivity.

  7. 7
    Malclès et al. SAFODEX (2017),DOI10.1097/IAE.0000000000001369

    Complete indexed primary abstract read; full report/tables unread. Retrospective,heterogeneous indications,eye-based denominator and repeated exposure; OHT is not a universal high-responder rate.

  8. 8
    EMA. Ozurdex EU product information

    Official PDF retrieved locally after web429; SmPC sections4.3/4.4 directly read,including contraindications,migration and IOP monitoring. Not every section/language or current device IFU inspected.

  9. 9
    RCOphth. Retinal vein occlusion guideline executive summary (January2022)

    Official PDF selected neovascular/established-NVG recommendations pp4–5 read. Cover says January2022,review due January2025;2026 hosting path is not a new guideline edition. CRVO-specific context,not every NVG cause.

  10. 10
    Choi and Kwon. Dexamethasone OHT risk cohort (2020),PMID32792579

    Complete indexed primary abstract and selected indexed methods/result passages read; direct PMC challenged; full report unread. Small retrospective DME cohort,limited events and local thresholds.

  11. 11
    Xiao and Qiu. Ozurdex OHT management cohort (2025),DOI10.1016/j.ajoc.2025.102274

    Complete indexed primary abstract,selected main methods/results/limitations and extracted table2 inspected. Full narrative/supplements/figure pixels unread. Available-case follow-up and repeated eyes/implants require caution; no random procedure comparison.

  12. 12
    Original derivative lecture and three video links

    Complete current page and companion SOAG topic read; exact lecture/table duplication independently checked. Videos,slides and spoken transcript unread. Video attribution differs across the duplicate pages.

  13. 13
    Terelak-Borys et al. Ocular ischaemic syndrome review (2012),PMID22847215

    Complete indexed review abstract and selected indexed summary passages read; full review/source studies unread. Historical review for cause/differential context,not a newly verified revascularisation protocol.

  14. 14
    AAO. Retinal Vein Occlusions Preferred Practice Pattern,current hosted PDF

    Official PDF retrieved locally after browser403. Selected natural-history,treatment and examination text printed pp315–317 read; full PPP/figures/tables not read. Cover approval September2024; a footnote updated through June2026. Filename2026 is not proof of a wholly new approval.

Original lecture links